Fennec Pharmaceuticals
(NASDAQ) FENC
Fennec Pharmaceuticals Financials at a Glance
Market Cap
$235.81M
Revenue (TTM)
$44.85M
Net Income (TTM)
$10.18M
EPS (TTM)
$-0.34
P/E Ratio
-19.88
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$6.86
Volume
2,499
Open
$6.59
Price
$6.86
Volume
2,499
Open
$6.59
Previous Close
$6.86
Daily Range
$6.59 - $6.98
52-Week Range
$5.58 - $9.92
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$6.86
Volume
2,499
Open
$6.59
Previous Close
$6.86
Daily Range
$6.59 - $6.98
52-Week Range
$5.58 - $9.92
FENC News
FENC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Fennec Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
35
CEO
Jeffrey S Hackman
Website
www.fennecpharma.comHeadquarters
Research Triangle Park, NC 27709, US
FENC Financials
Key Financial Metrics (TTM)
Gross Margin
92%
Operating Margin
-15%
Net Income Margin
-23%
Return on Equity
-68%
Return on Capital
-11%
Return on Assets
-15%
Earnings Yield
-5.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$235.81M
Shares Outstanding
34.48M
Volume
2.50K
Short Interest
0.00%
Avg. Volume
165.82K
Financials (TTM)
Gross Profit
$41.59M
Operating Income
$6.86M
EBITDA
$6.86M
Operating Cash Flow
$12.47M
Capital Expenditure
$0.00
Free Cash Flow
$12.47M
Cash & ST Invst.
$36.72M
Total Debt
$0.00
Fennec Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$13.99M
+76.5%
Gross Profit
$12.20M
+68.1%
Gross Margin
87.20%
N/A
Market Cap
$235.81M
N/A
Market Cap/Employee
$7.37M
N/A
Employees
32
N/A
Net Income
$5.22M
-163.1%
EBITDA
$3.06M
-236.9%
Quarterly Fundamentals
Net Cash
$36.72M
+403.4%
Accounts Receivable
$23.18M
+79.9%
Inventory
$1.56M
+47.4%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
-100.0%
Return on Assets
-14.53%
N/A
Return on Invested Capital
-11.40%
N/A
Free Cash Flow
$5.96M
-304.5%
Operating Cash Flow
$5.96M
-304.5%